Precursor Cell Lymphoblastic Leukemia-lymphoma
📧 Sign up to get email alerts when something new happens for Precursor Cell Lymphoblastic Leukemia-lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-12Clinical Trial Results: Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation [NA]
A completed clinical trial evaluating an electronic mindfulness-based music therapy intervention for patients undergoing allogeneic stem cel…
-
EMA approval · 2026-03-06EMA Authorised: Sprycel (dasatinib) — Bristol-Myers Squibb Pharma EEIG
The EMA authorised Sprycel (dasatinib). It covers chronic myeloid leukemia (BCR-ABL positive) and precursor cell lymphoblastic leukemia-lymp…
-
EMA approval · 2026-03-05EMA Authorised: Imatinib Teva (imatinib) — Teva B.V.
EMA authorised Imatinib Teva (imatinib) for multiple indications including chronic myeloid leukemia, precursor cell lymphoblastic leukemia-l…
-
EMA approval · 2026-02-19EMA Authorised: Enrylaze (crisantaspase) — Jazz Pharmaceuticals Ireland Limited
Enrylaze (crisantaspase) has been authorised by the EMA for precursor cell lymphoblastic leukemia-lymphoma.
-
EMA approval · 2025-11-12EMA Authorised: Glivec (imatinib) — Novartis Europharm Limited
The European Medicines Agency authorised Glivec (imatinib) for multiple indications, including precursor cell lymphoblastic leukemia-lymphom…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-06-18EMA Authorised: Phelinun (melphalan hydrochloride) — ADIENNE S.r.l. S.U.
The EMA authorised Phelinun (melphalan hydrochloride) for multiple cancers including multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphom…
-
EMA approval · 2025-05-06EMA Authorised: Imatinib Accord (imatinib) — Accord Healthcare S.L.U.
The EMA authorised Imatinib Accord (imatinib) for several indications, including Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dermatofibr…
-
CLINICAL_TRIALS research · 2025-03-14Clinical Trial Update: Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia [Phase 2]
Phase 2 clinical trial update on the effectiveness of probiotics to prevent gastrointestinal toxicity in children with leukemia, with enroll…
-
EMA approval · 2024-10-25EMA Authorised: Oncaspar (pegaspargase) — Les Laboratoires Servier
The European Medicines Agency authorised Oncaspar (pegaspargase) from Les Laboratoires Servier for precursor cell lymphoblastic leukemia-lym…
-
EMA approval · 2024-07-22EMA Authorised: Evoltra (clofarabine) — Sanofi B.V.
The European Medicines Agency authorised Evoltra (clofarabine) for the treatment of precursor cell lymphoblastic leukemia-lymphoma, with San…
-
CLINICAL_TRIALS trial_result · 2024-03-19Clinical Trial Update: NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) [Phase 1, Phase 2]
Phase 1/2 clinical trial update on NK donor lymphocyte infusion following HLA-haploidentical HSCT; study status completed.
-
EMA withdrawal · 2023-12-07EMA Withdrawn: Ivozall (clofarabine) — ORPHELIA Pharma
EMA has withdrawn Ivozall (clofarabine) from the market for the therapeutic area of precursor cell lymphoblastic leukemia-lymphoma.
-
EMA approval · 2023-11-20EMA Authorised: Spectrila (asparaginase) — Medac Gesellschaft fuer klinische Spezialpraeparate mbH
The EMA authorised Spectrila (asparaginase) for precursor cell lymphoblastic leukemia-lymphoma (ALL/LBL) in collaboration with Medac as the …
-
EMA withdrawal · 2023-10-19EMA Withdrawn: Imatinib Koanaa (imatinib mesilate) — Koanaa Healthcare GmbH
The EMA status shows Imatinib Koanaa (imatinib mesilate) has been withdrawn from the market by Koanaa Healthcare GmbH.
-
EMA withdrawal · 2023-03-30EMA Withdrawn: Dasatinib Accordpharma (dasatinib) — Accord Healthcare S.L.U.
The EMA has withdrawn the dasatinib product Accordpharma from Accord Healthcare S.L.U. for indications including precursor cell lymphoblasti…
-
EMA withdrawal · 2023-03-30EMA Withdrawn: Dasatinib Accord (dasatinib) — Accord Healthcare S.L.U.
The EMA has withdrawn the Dasatinib Accord product (dasatinib) from Accord Healthcare S.L.U., applicable to precursor cell lymphoblastic leu…
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: InO - A Retrospective Study of UK Patients With Leukaemia
A retrospective UK study of InO (inotuzumab ozogamicin) in patients with precursor cell lymphoblastic leukemia-lymphoma has been completed w…
-
CLINICAL_TRIALS trial_result · 2020-07-08Clinical Trial Update: Nutrition and Body Composition in Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 trial updating on nutrition and body composition in precursor cell lymphoblastic leukemia-lymphoma with vitamin D deficiency; study …
-
EMA withdrawal · 2019-10-16EMA Withdrawn: Imatinib medac (imatinib) — Medac
The EMA has withdrawn Imatinib Medac (imatinib) from the market.
-
CLINICAL_TRIALS trial_result · 2019-10-16Clinical Trial Update: Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation [Phase 1, Phase 2]
Phase 1/2 clinical trial of azacitidine in patients undergoing matched unrelated donor stem cell transplantation has been terminated; result…
-
EMA withdrawal · 2019-01-23EMA Application withdrawn: Graspa (asparaginase) — ERYTECH Pharma S.A.
EMA withdrawal of Graspa (asparaginase) application for Precursor Cell Lymphoblastic Leukemia-Lymphoma.
-
CLINICAL_TRIALS research · 2018-07-24Clinical Trial Update: Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial evaluating Rituximab in combination with mVPDL for CD20-positive precursor cell lymphoblastic leukemia-lymphoma in ad…
-
CLINICAL_TRIALS trial_result · 2018-03-13Clinical Trial Update: De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL) [NA]
This clinical trial update discusses a de-escalated treatment approach being studied in adults with Ph-negative acute lymphoblastic leukemia…
-
EMA withdrawal · 2017-04-25EMA Application withdrawn: Graspa — ERYTECH Pharma S.A.
EMA has withdrawn the application for Graspa by ERYTECH Pharma S.A., in the therapeutic area of Precursor Cell Lymphoblastic Leukemia-Lympho…